CHR Chr. Hansen Holding A/S

Chr. Hansen launches 2025 Strategy with the ambition to create a differentiated bioscience leader to improve food and health for a sustainable future

Chr. Hansen launches 2025 Strategy with the ambition to create a differentiated bioscience leader to improve food and health for a sustainable future

Company Announcement No. 20/2020

August 24, 2020

Please see the full announcement in the attached document. 

  • 2025 Strategy founded in strong purpose: “Grow a better world. Naturally”
  • Exciting growth and innovation opportunities across food, health and agriculture; new lighthouse in Fermented Plant Bases announced
  • Chr. Hansen to focus investments on Microbial Platform going forward; strategic review of Natural Colors progressing well
  • New long-term financial and non-financial ambitions until 2024/25

Chr. Hansen Holding A/S (“Chr. Hansen” or “the Company”) today released its 2025 Strategy with the ambition to create a differentiated bioscience company with focus on its microbial and fermentation technology platforms putting Food Cultures & Enzymes and Health & Nutrition at the center of its new strategy. During the strategy period which runs until the end of the financial year 2024/25, Chr. Hansen’s long-term financial ambition is to deliver mid- to high single-digit organic growth, averaged over the period. Furthermore, the Company plans to increase its underlying EBIT margin before special items, before portfolio changes and currency impacts, with efficiency gains and scalability benefits from operations, as well as synergies from recent acquisitions, to be partly reinvested into the business during the strategy period. Average growth in free cash flow before acquisitions and special items is expected to exceed the average absolute EBIT growth.

CEO Mauricio Graber says: “Chr. Hansen has undertaken a tremendous journey since its start as an ingredient supplier to the dairy industry, and I feel very proud to lead a company with such a strong purpose and so many exciting growth prospects. With the launch of our 2025 Strategy we are stepping up our game to unlock the next wave of value creation by advancing Chr. Hansen into a focused global bioscience player that specializes in fermentation technology and microbial solutions. With this focus we will be uniquely positioned and clearly stand out in our industry.”

“At Chr. Hansen, we will continue to pioneer microbial science to improve food and health, for a more sustainable future. Already today, more than 80% of our revenue contribute to the United Nation’s Sustainable Development Goals, and we are committed to continuing to leverage the Power of Good Bacteria™ which is also reflected in our newly defined purpose: ‘Grow a better world. Naturally.’”

Virtual Capital Markets Day 2020

On the occasion of its strategy launch and as part of its virtual Capital Markets Day 2020 which includes a live Q&A webcast with management on August 25, 2020, at 3:00 p.m. CEST, Chr. Hansen has released a microsite with pre-recorded management presentations and further materials. Investors and analysts are strongly encouraged to watch the videos before the live webcast. You can access the CMD microsite directly here: bit.ly/CHR-CMD2020

For further information please contact:

Martin Riise, Head of Investor Relations, Tel:

Annika Stern, Investor Relations Officer, Tel:

Camilla Lercke, Head of Media Relations, Tel:

About Chr. Hansen

Chr. Hansen is a leading, global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. We develop and produce cultures, enzymes, probiotics and natural colors for a rich variety of foods, confectionery, beverages, dietary supplements and even animal feed and plant protection. Our product innovation is based on around 40,000 microbial strains – we like to refer to them as ‘good bacteria’. Our solutions enable food manufacturers to produce more with less – while also reducing the use of chemicals and other synthetic additives – which make our products highly relevant in today’s world. Sustainability is an integral part of Chr. Hansen’s vision to improve food and health. In 2019 Chr. Hansen was ranked as the world’s most sustainable company by Corporate Knights thanks to our strong sustainability efforts and our many collaborative partnerships with our customers. We have been delivering value to our partners – and, ultimately, end consumers worldwide – for over 140 years. We are proud that more than one billion people consume products containing our natural ingredients every day.

Attachment

EN
24/08/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Chr. Hansen Holding A/S

Rune Majlund Dahl
  • Rune Majlund Dahl

Chr. Hansen (No_rec, TP: DKK) - Discontinuing coverage

We have discontinued coverage of Chr. Hansen in light of its combination with Novozymes. Our last published recommendation, target price, and estimates should no longer be relied upon.

 PRESS RELEASE

Completion of the combination between Novozymes and Chr. Hansen

Completion of the combination between Novozymes and Chr. Hansen January 29, 2024 – Company announcement no. 2 Please see attachment. CONTACT INFORMATION Investor Relations Tobias Cornelius Bjorklund Anders Enevoldsen Press Relations Lina Danstrup Attachment

 PRESS RELEASE

All necessary regulatory approvals have been obtained for the combinat...

All necessary regulatory approvals have been obtained for the combination of Novozymes and Chr. Hansen January 26, 2024 – Company announcement no. 1 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

Rune Majlund Dahl
  • Rune Majlund Dahl

Chr. Hansen (Hold, TP: DKK582.00) - Down to HOLD, target price raised

We forecast Chr. Hansen to reach the high end of its 2023 guidance of 10–12% organic revenue growth and a 26–27% EBIT margin, but expect the combined entity (Novonesis) to issue a new guidance upon completion of the merger. As Chr. Hansen shareholders are set to receive 1.5236 new B-shares in Novonesis, the changes in our Novozymes model translate into a raised Chr. Hansen target price of DKK582 (536), and we have thus downgraded to HOLD (BUY).

 PRESS RELEASE

Update on the merger approval process for the combination of Novozymes...

Update on the merger approval process for the combination of Novozymes and Chr. Hansen: South Korean merger approval granted December 20, 2023 Please see attachment. Contact information Investor RelationsDisa Tuominen Press RelationsSanne Seyer-Hansen Attachment

ResearchPool Subscriptions

Get the most out of your insights

Get in touch